Phase I–II Parallel Study of Docetaxel on a Bimonthly Schedule in Refractory Metastatic Breast Carcinoma

被引：8

作者：

Vittorio Gebbia

Nicolò Borsellino

Antonio Testa

Maria Lina Tirrito

Patrizia Ferrera

Alfredo Colombo

Gaetano Mauceri

Antonio Marrazzo

Ferdinando Porretto

Maurizio Musso

机构：

[1] University of Palermo,Institute of Clinical Medicine

[2] La Maddalena Clinic for Cancer,Divisions of Medical Oncology, Breast Cancer Unit, and Oncohematology

[3] Casa di Cura Torina,Service of Oncology

[4] Centro Catanese di Oncologia,Division of Medical Oncology

来源：

Breast Cancer Research and Treatment | 2003年 / 77卷

关键词：

bimonthly schedule; breast cancer; docetaxel; metastasis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background. The 3-week schedule with docetaxel (DTC) 75–100 mg/m2 is associated with severe neutropenia, gastro-intestinal side-effects and fluid retention in a significant proportion of patients, which may be of concern in more elderly or poor performance status patients. A phase I–II trial was carried out to test the feasibility and the activity of a new bimonthly schedule of DCT.

引用

页码：99 / 108

页数：9

共 50 条

[1] Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma
Gebbia, V
Borsellino, N
Testa, A
Tirrito, ML
Ferrera, P
Colombo, A
Mauceri, G
Marrazzo, A
Porretto, F
Musso, M
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (02) : 99 - 108
[2] Phase I-II parallel study of docetaxel (DCT) on a bi-monthly schedule in refractory metastatic breast carcinoma (MNC).
Gebbia, V
Borsellino, N
Testa, A
Tirrito, M
Mauceri, G
Ferrera, P
[J]. ANNALS OF ONCOLOGY, 2000, 11 : 43 - 43
[3] A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma
Tiersten, AD
Nelsen, C
Talbot, S
Vahdat, L
Fine, R
Troxel, A
Brafman, L
Shriberg, L
Antman, K
Petrylak, DP
[J]. CANCER, 2003, 97 (03) : 537 - 544
[4] Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma
Tester, William
Ackler, Joann
Tijani, Lukman
Leighton, John
[J]. CANCER JOURNAL, 2006, 12 (04): : 299 - 304
[5] Weekly docetaxel in pretreated metastatic breast cancer: A phase I/II study
Adami, F
Aitini, F
Cavazzini, G
Cantore, M
Rabbi, C
Pari, F
Zamagni, D
Sorio, M
Smerieri, F
[J]. ANNALS OF ONCOLOGY, 2000, 11 : 35 - 35
[6] Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
Buch-Hansen, Trine Zeeberg
Bentzen, Lise
Hansen, Steinbjoern
Hoeyer, Morten
Jensen, Niels Viggo
Saxe, Charlotte
Sengeloev, Lisa
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 295 - 301
[7] Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
Trine Zeeberg Buch-Hansen
Lise Bentzen
Steinbjoern Hansen
Morten Hoeyer
Niels Viggo Jensen
Charlotte Saxe
Lisa Sengeloev
[J]. Cancer Chemotherapy and Pharmacology, 2010, 66 : 295 - 301
[8] Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: A phase I/II study
Cals, L
Nouyrigat, P
Valenza, B
Pedinelli, FJ
Juin, P
[J]. ONCOLOGY, 2004, 67 (3-4) : 257 - 261
[9] Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
Rivera, E
Holmes, FA
Frye, D
Valero, V
Theriault, RL
Booser, D
Walters, R
Buzdar, AU
Dhingra, K
Fraschini, G
Hortobagyi, GN
[J]. CANCER, 2000, 89 (11) : 2195 - 2201
[10] Weekly docetaxel in pretreated metastatic breast cancer patients:: A phase I-II study
Nisticò, C
Cognetti, F
Frontini, L
Barni, S
Ferretti, G
Bria, E
Milella, M
Garufi, C
Cuppone, F
Vanni, B
Carlini, P
Terzoli, E
[J]. ONCOLOGY, 2005, 68 (4-6) : 356 - 363

← 1 2 3 4 5 →